ECSP10010384A - Nuevas piridinonas y piridazinonas - Google Patents

Nuevas piridinonas y piridazinonas

Info

Publication number
ECSP10010384A
ECSP10010384A EC2010010384A ECSP10010384A ECSP10010384A EC SP10010384 A ECSP10010384 A EC SP10010384A EC 2010010384 A EC2010010384 A EC 2010010384A EC SP10010384 A ECSP10010384 A EC SP10010384A EC SP10010384 A ECSP10010384 A EC SP10010384A
Authority
EC
Ecuador
Prior art keywords
iii
btk
compounds
phenyl
useful
Prior art date
Application number
EC2010010384A
Other languages
English (en)
Inventor
Nolan James Dewdney
Joshua Kennedy-Smith
Rama K Kondru
Bradley E Loe
Yan Lou
Joel Mcintosh
Timothy D Owens
Michael Soth
Zachary Kevin Sweeney
Joshua Paul Gergely Taygerly
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP10010384A publication Critical patent/ECSP10010384A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta solicitud se refiere a derivados de 5-fenil-1H-piridin-2-ona y 6-fenil-2H-piridazin-3-ona de las fórmulas genéricas I-III: (I) (II) (III)en las que las variables R, X, Y1, Y2, Y3, Y4, n y m tienen los significados definidos anteriormente, que inhiben la Btk. Los compuestos aquí descritos son útiles para modular la actividad de la Btk y tratar enfermedades asociadas con una actividad excesiva de la Btk. Además, estos compuestos son útiles para tratar enfermedades inflamatorias y autoinmunes asociadas con la proliferación aberrante de células B, por ejemplo la artritis reumatoide. Se describen también composiciones que contienen los compuestos de las fórmulas I-III y por lo menos un vehículo, diluyente o excipiente.
EC2010010384A 2008-02-05 2010-08-05 Nuevas piridinonas y piridazinonas ECSP10010384A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2620408P 2008-02-05 2008-02-05
US12251008P 2008-12-15 2008-12-15

Publications (1)

Publication Number Publication Date
ECSP10010384A true ECSP10010384A (es) 2010-09-30

Family

ID=40413736

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010384A ECSP10010384A (es) 2008-02-05 2010-08-05 Nuevas piridinonas y piridazinonas

Country Status (30)

Country Link
EP (1) EP2242749B1 (es)
JP (1) JP5259739B2 (es)
KR (1) KR101308803B1 (es)
CN (1) CN101932573B (es)
AR (1) AR070408A1 (es)
AU (1) AU2009211514B2 (es)
BR (1) BRPI0907915A2 (es)
CA (1) CA2710462C (es)
CL (1) CL2009000229A1 (es)
CO (1) CO6290767A2 (es)
CR (1) CR11598A (es)
CY (1) CY1114114T1 (es)
DK (1) DK2242749T3 (es)
EC (1) ECSP10010384A (es)
ES (1) ES2420846T3 (es)
HK (1) HK1146826A1 (es)
HR (1) HRP20130615T1 (es)
IL (1) IL206357A (es)
MA (1) MA32064B1 (es)
MX (1) MX2010008197A (es)
MY (1) MY158411A (es)
NZ (1) NZ586916A (es)
PE (1) PE20091484A1 (es)
PL (1) PL2242749T3 (es)
PT (1) PT2242749E (es)
RU (1) RU2505538C2 (es)
SI (1) SI2242749T1 (es)
TW (1) TWI382024B (es)
WO (1) WO2009098144A1 (es)
ZA (1) ZA201005539B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102066366B (zh) 2008-06-24 2014-04-16 霍夫曼-拉罗奇有限公司 新型取代的吡啶-2-酮和哒嗪-3-酮
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN102292329B (zh) * 2009-04-24 2014-09-03 霍夫曼-拉罗奇有限公司 布鲁顿酪氨酸激酶的抑制剂
EP2473049B1 (en) 2009-09-04 2018-11-28 Biogen MA Inc. Bruton's tyrosine kinase inhibitors
RU2017112518A (ru) * 2010-05-07 2019-01-25 Джилид Коннектикут, Инк. Пиридоновые и азапиридоновые соединения и способы применения
EP2394998A1 (en) * 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
AU2012257802A1 (en) * 2011-05-17 2013-10-31 F. Hoffmann-La Roche Ag Inhibitors of Bruton's tyrosine kinase
MX349372B (es) * 2011-08-17 2017-07-26 Hoffmann La Roche Inhibidores de la tirosina-cinasa de bruton.
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
CN104244939A (zh) 2012-04-05 2014-12-24 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
AU2013250726B2 (en) 2012-04-20 2017-01-05 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
US9499548B2 (en) * 2012-09-13 2016-11-22 Hoffmann-La Roche Inc. Inhibitors of bruton's tyrosine kinase
WO2014076104A1 (en) * 2012-11-16 2014-05-22 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
WO2014083026A1 (en) * 2012-11-30 2014-06-05 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
KR101737724B1 (ko) * 2013-03-05 2017-05-29 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
CN105143215B (zh) * 2013-03-05 2017-12-08 豪夫迈·罗氏有限公司 布鲁顿氏酪氨酸激酶抑制剂
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
DK2989106T3 (en) 2013-04-25 2017-03-20 Beigene Ltd CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEINKINASE INHIBITORS
CN104177338B (zh) * 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
CN110698481B (zh) * 2013-07-03 2023-02-28 豪夫迈·罗氏有限公司 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗pd−1抗体並びにその治療及び診断のための使用
EP3077384B1 (en) * 2013-12-05 2017-09-06 F. Hoffmann-La Roche AG Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
WO2016050921A1 (en) * 2014-10-02 2016-04-07 F. Hoffmann-La Roche Ag Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk)
EP3402789B1 (en) * 2016-01-13 2020-03-18 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
US20190105407A1 (en) 2016-03-31 2019-04-11 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
US11174243B2 (en) 2016-07-21 2021-11-16 Sunesis Pharmaceuticals, Inc. Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
MX2019001900A (es) 2016-08-16 2019-07-01 Beigene Ltd Forma cristalina de (s)-7-(1-acriloilpiperidin-4-il)-2-(4-fenoxife nil)-4,5,6,7-tetra-hidropirazolo[1,5-a]pirimidin-3-carboxamida, preparacion y usos de la misma.
CN110087680B (zh) 2016-08-19 2024-03-19 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
MA46285A (fr) 2016-09-19 2019-07-31 Mei Pharma Inc Polythérapie
TWI774726B (zh) 2017-01-25 2022-08-21 英屬開曼群島商百濟神州有限公司 (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途
CN106967073A (zh) * 2017-04-24 2017-07-21 刘双伟 一种治疗类风湿性关节炎的药物
CN108164536A (zh) * 2017-05-08 2018-06-15 刘双伟 一种用于治疗类风湿性关节炎的新的化合物的合成方法
AU2018290532A1 (en) 2017-06-26 2019-11-21 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
CN110997677A (zh) 2017-08-12 2020-04-10 百济神州有限公司 具有改进的双重选择性的Btk抑制剂
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
WO2020081450A1 (en) 2018-10-15 2020-04-23 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
EP3953346A1 (en) 2019-04-09 2022-02-16 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
US11530229B2 (en) 2019-05-17 2022-12-20 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021091575A1 (en) * 2019-11-08 2021-05-14 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
AU2020397920A1 (en) 2019-12-04 2022-06-16 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3214729A1 (en) 2021-04-08 2022-10-13 Marilena GALLOTTA Combination therapies with cbl-b inhibitor compounds
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3951395B2 (ja) * 1996-12-13 2007-08-01 田辺製薬株式会社 ピリジン誘導体、その製法及びその合成中間体
NZ514711A (en) * 1999-03-12 2004-02-27 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
ES2232306B1 (es) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
EP1831168B1 (en) * 2004-12-16 2014-07-02 Vertex Pharmaceuticals Inc. Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases.
JP4937135B2 (ja) * 2004-12-24 2012-05-23 アストラゼネカ・アクチエボラーグ アミド誘導体
EP1863766B1 (en) * 2005-03-10 2015-05-20 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
WO2006124731A2 (en) * 2005-05-12 2006-11-23 Irm Llc Compounds and compositions as protein kinase inhibitors
US7868018B2 (en) * 2005-08-09 2011-01-11 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2006285038A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases
BRPI0711628A2 (pt) * 2006-05-15 2011-12-06 Irm Llc composto, composição farmacêutica, uso e processo para preparação do composto

Also Published As

Publication number Publication date
DK2242749T3 (da) 2013-06-17
TW200938538A (en) 2009-09-16
ZA201005539B (en) 2011-04-28
ES2420846T3 (es) 2013-08-27
PL2242749T3 (pl) 2013-09-30
JP2011511027A (ja) 2011-04-07
KR101308803B1 (ko) 2013-09-13
PE20091484A1 (es) 2009-10-03
MA32064B1 (fr) 2011-02-01
JP5259739B2 (ja) 2013-08-07
CO6290767A2 (es) 2011-06-20
CA2710462C (en) 2015-11-24
CL2009000229A1 (es) 2010-06-04
AR070408A1 (es) 2010-04-07
WO2009098144A1 (en) 2009-08-13
MY158411A (en) 2016-10-14
EP2242749B1 (en) 2013-04-10
EP2242749A1 (en) 2010-10-27
NZ586916A (en) 2012-06-29
AU2009211514A1 (en) 2009-08-13
CN101932573B (zh) 2014-06-11
CA2710462A1 (en) 2009-08-13
PT2242749E (pt) 2013-07-16
IL206357A (en) 2013-12-31
HRP20130615T1 (en) 2013-08-31
RU2505538C2 (ru) 2014-01-27
CR11598A (es) 2010-10-27
BRPI0907915A2 (pt) 2015-07-28
IL206357A0 (en) 2010-12-30
SI2242749T1 (sl) 2013-07-31
CN101932573A (zh) 2010-12-29
KR20100093130A (ko) 2010-08-24
CY1114114T1 (el) 2016-07-27
RU2010136665A (ru) 2012-03-20
TWI382024B (zh) 2013-01-11
AU2009211514B2 (en) 2014-02-20
HK1146826A1 (en) 2011-07-15
MX2010008197A (es) 2010-08-23

Similar Documents

Publication Publication Date Title
ECSP10010384A (es) Nuevas piridinonas y piridazinonas
ECSP10010709A (es) Nuevas piridin-2-onas y piridazin-3-onas sustituidas
ECSP13012437A (es) Inhibidores de la tirosina-quinasa de bruton
ECSP13013025A (es) Inhibidores de la tirosina-quinasa de bruton
ECSP14013212A (es) Inhibidores de la tirosina-quinasa de bruton
PE20151336A1 (es) Inhibidores de la tirosina-quinasa de bruton
NI201200190A (es) Composiciones y métodos para modular la vía de señalización de wnt
CL2011002726A1 (es) Compuestos derivados de sulfonamidas, sus n-oxidos y sus sales; composicion que los comprende; metodo para controlar un nematodo parasitico y semilla tratada.
CO6680683A2 (es) Inhibiddores de la prostaglandina e2 sintasa-1 microsómica (mpges-1) y composiciones que los contienen, útiles en el tratamiento de enfermedades inflamatorias
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
CO6450669A2 (es) Composiciones y metodos para modular la senda de señalizacion de wnt
CY1114223T1 (el) Πρωτοτυπες φαινυλοπυραζινονες ως αναστολεις κινασης
EA200900397A1 (ru) Новые соединения диосметина, способ их получения и фармацевтические композиции, которые их содержат
EA200970987A1 (ru) Трициклические азотсодержащие соединения в качестве антибактериальных агентов
UY32723A (es) Compuestos de triazol que portan un sustituyente de azufre x
UY31925A (es) Isoquinolinas e isoquinolinonas sustituidas
UY29613A1 (es) Compuestos quimicos vi
DOP2008000089A (es) 18-metil-19-nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen
BR112014013582A8 (pt) inibidores de quinase de tirosina de bruton
ECSP088527A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
UY29607A1 (es) Compuestos quimicos
UY31750A (es) Compuestos y composiciones como inhibidores de quinasa
ECSP088156A (es) Compuestos farmacéuticos novedosos
NI200900147A (es) Nuevos derivados tricíclicos su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
SV2009003253A (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion